- 精神分裂症遗传风险与智商降低关...
- 非典型抗精神病药在青少年使用性...
- 产前服用抗癫痫药物丙戊酸钠增加...
- 老年患者使用抗精神病药要注意的
- 抗高血压药物硝普钠适用治疗精神...
- 吃出好心情
- 叶酸和精神疾病
- 5个简单问题预测精神病人的暴力...
- 门冬氨酸受体抗体在精神分裂症升...
- ω- 3脂肪酸和精神疾病
- 孕烯醇酮治疗精神分裂症的可能性
- 硝普钠迅速缓解精神分裂症的症状
- 痴呆的补充和替代疗法
- 产前服用抗癫痫药物丙戊酸钠增加...
- 噩梦的失眠可以关联抑郁症患者自...
- 睡眠质量预测临床前阿尔茨海默氏...
- 以色列科学家找出精神分裂症新的...
- (转)“灾难”让临床心理学家学...
- 治疗焦虑障碍的失眠
- 大脑中谷氨酸增高致精神分裂症
- 双相抑郁治疗和预防国际共识
- 多基因因素导致精神分裂症风险
- 精神分裂症的复发常有更多的尿路...
- 世界卫生组织对中国(H7N9)...
- 治疗强迫症的药物
- 非典型抑郁的诊断与治疗
- 对尚不能诊断为精神分裂症或精神...
- 治疗精神分裂症的问题(颜文伟)
- 快乐睡眠
- 光治疗改善老年抑郁症
- 催产素改善孤独症
- 经颅磁刺激治疗改善精神分裂症的...
- 轻度躯体异态可能反映出精神分裂...
- 精神分裂症与双相障碍的神经软体...
- 精神分裂症早期就要预防代谢疾病...
- 社交功能损害可能是精神分裂症早...
- 儿童双相障碍往往首发为抑郁症状
- 双相情感障碍和精神分裂症的社会...
- 精神分裂症患者并发症和死亡
- 怀孕期间使用SSRI死胎和新生...
- “抗氧化剂对有遗传脆弱性精神分...
- 血锂浓度正常的锂中毒 (喻东山...
- 补充叶酸和维生素B12可改善精...
- 赌博成瘾显示大脑白质异常类似物...
- 苯二氮卓类与致命的肺炎相关联
- FDA推荐低剂量唑吡坦用于失眠...
- 双相情感障碍存在代谢综合征危险...
- NMDA受体的抗抑郁作用
- 抗精神病药物的抗抑郁效果
- 焦虑症状的自我改善
- FDA requires sl...
- 未被发现的疾病增加精神分裂症的...
- 补充维生素C增加男性肾结石的风...
- FDA-approved me...
- 精神分裂症的不良饮食习惯易引起...
- 难治性精神分裂症与种族
- 难治性精神分裂症
- 精神病治疗的新方法
- 抗抑郁药物撤药症状
- 服用SSRIs增加脑出血的风险
- 童年急性应激增加精神障碍的风险
- 空气污染与儿童孤独症
- 酒精依赖的康复
- 处理酒精戒断症状
- The average lif...
- 证据显示突变基因引发精神分裂症
- 治疗强迫症
- 治疗强迫症进展
- 饮食与精神健康
- 膳食补充剂对精神分裂症的预防提...
- 服抗精神病药前需要向医生问些什...
- 治疗焦虑症的药物
- 治疗双相障碍的药物
- 治疗精神分裂症的药物
- 非典型抗精神病药对儿童情感障碍...
- 研究提示:青少年双相障碍患病率...
- 能对抗抑郁药快速反应的脑中的生...
- 迅速短暂缓解抑郁的研究
- FDA对安眠药唑吡坦提出安全警...
- 联合使用抗抑郁药
- 精神疾病急性期治疗
- 精神疾病急性期治疗
- 使用抗精神病药基本原则
- 拮抗大脑中的谷氨酸盐可以防止自...
- 起效迅速 疗效持久的抗抑郁药问...
- 缺乏共情可能是精神障碍的特点
- 抑郁症患者中有不少是双相障碍
- 在中国文化程度低患精神分裂症的...
- 认识不够使治疗双相障碍治疗时间...
- 亚临床的双相抑郁
- 妊娠早期精神压力过大,增加孩子...
- 精神分裂症疗效不好时?
- FDA-批准的治疗酒精依赖药物
- “毒品”疫苗:药物依赖令人激动...
- 治疗迟发性运动障碍
- 美国食品和药物管理局批准另一个...
- 妊娠期是否服用抗抑郁药:一个艰...
- 睡眠不足会导致精神分裂症的症状...
- 精神障碍的危险因素与保护因素
- 缓解强迫症
- 大脑训练可以帮助提高老年人特定...
- 大脑训练可以帮助提高老年人特定...
- 科学解释:人们在得到鼓励后为何...
- 老年人服用苯二氮卓类药物可能增...
- 老年人服用苯二氮卓类药物可能增...
- 运动有益于精神分裂症患者的身体...
- 运动有益于精神分裂症患者的身体...
- 预防老年痴呆
- 预防老年痴呆
- 科学家荣获2012精神医学研究...
- 2011年美国农业部和美国卫生...
- 2011年美国农业部和美国卫生...
- 美国食品和药物管理局批准使用的...
- 美国食品和药物管理局批准使用的...
- 美国的各类精神障碍患者数量及患...
- 美国的各类精神障碍患者数量及患...
- 精神分裂症的早期征象
- 精神分裂症的早期征象
- 精神疾病与季节
- 精神疾病与季节
- 使人心情抑郁的十种药
- 使人心情抑郁的十种药
- 叶酸与抑郁症
- 叶酸与抑郁症
- 欧洲药品管理局建议降低西太普兰...
- 欧洲药品管理局建议降低西太普兰...
- 增加点维生素D可以减轻抑郁
- 增加点维生素D可以减轻抑郁
- 抗精神病药疗效降低的可能原因 ...
- 抗精神病药疗效降低的可能原因 ...
- 精神分裂症复发的早期表现
- 精神分裂症复发的早期表现
- 降低精神分裂症患病风险的策略
- 降低精神分裂症患病风险的策略
- 基因不是命运
- 基因不是命运
- 阿尔茨海默氏症治疗
- 阿尔茨海默氏症治疗
- 缓解精神压力小技巧
- 缓解精神压力小技巧
- 抗抑郁药临床治疗的选择[转载]
- 抗抑郁药临床治疗的选择[转载]
- 对精神疾病一些认识误区 (摘...
- 对精神疾病一些认识误区 (摘...
- 精神病药物疗效差的可能因素
- 精神病药物疗效差的可能因素
- 识别精神病的早期症状
- 识别精神病的早期症状
- 引起或诱发双相障碍的原因
- 引起或诱发双相障碍的原因
- the potential f...
- the potential f...
- 抑郁症与低胆固醇
- 抑郁症与低胆固醇
- 抑郁症复发的高危因素
- 抑郁症复发的高危因素
- 抗抑郁药物的停药一些问题
- 抗抑郁药物的停药一些问题
- 儿童孤独症的药物治疗
- 儿童孤独症的药物治疗
- 精神分裂症巩固期的合并用药
- 精神分裂症巩固期的合并用药
- Psychotropic Me...
- Psychotropic Me...
- ECT的副反应
- ECT的副反应
- 双相障碍药物长期治疗的一些问题
- 双相障碍药物长期治疗的一些问题
- 电休克治疗中 adequate...
- 电休克治疗中 adequate...
- 治疗迟发性运动障碍的药物
- 治疗迟发性运动障碍的药物
- 如何睡的更好
- 如何睡的更好
- 草药能否治疗抑郁症?
- 草药能否治疗抑郁症?
- 季节性情感障碍
- 季节性情感障碍
- 一小时内缓解抑郁症(Scien...
- 一小时内缓解抑郁症(Scien...
- 患双相情感障碍年轻女性在服用丙...
- 患双相情感障碍年轻女性在服用丙...
- 妊娠期电休克治疗的安全性
- 妊娠期电休克治疗的安全性
- 科学家荣获2012精神医学研究奖
- 作者:朱健民|发布时间:2012-10-29|浏览量:471次
Scientists Honored For Outstanding Achievements in Mental Health Research
(GREAT NECK, N.Y. ? September 20, 2012) The Brain & Behavior Research Foundation will celebrate 25 years of Empowering Research for Productive Lives by honoring eight extraordinary scientists at its Annual National Awards Dinner to be held at the Pierre Hotel in New York City on October 26.江西省精神病医院精神科朱健民
“Each year, the Foundation recognizes outstanding leadership and contributions to mental health research with a number of annual prizes. Together these prizes are known as the Outstanding Achievement Prizes and are recognized by scientists as among the most prestigious honors possible in the field,” said Benita Shobe, Foundation President and CEO. Selected through a peer-review process of the Brain & Behavior Research Foundation Scientific Council, a volunteer group of 138 pre-eminent mental health researchers, the prizes often mark the culmination of career achievements in furthering the understanding and treatment of mental illness.
In addition to the awards for scientists, the Foundation will give Productive Lives Awards to two individuals who have risen to the top of their respective professions and have devoted their energy and formidable talents to helping those living with mental illness live productive lives.
This year"s Outstanding Achievement Prizewinners are:
The Lieber Prize for Outstanding Achievement in Schizophrenia Research
Michael O’Donovan, M.D., Ph.D., Cardiff University
Michael J. Owen, M.D., Ph.D., Cardiff University
Drs. O’Donovan and Owen are both Fellows of the Royal College of Psychiatrists and are among the United Kingdom’s leading mental health researchers.
Dr. O’Donovan is Deputy Director of the Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics and of the Institute of Psychological Medicine and Clinical Neurosciences at Cardiff University School of Medicine, in Wales, where he is also Professor of Psychiatric Genetics. The main focus of his research has been on the genetics of schizophrenia and on basic laboratory methods related to genomics and gene regulation. His landmark research with Michael Owen involves the application of molecular genetic technology to identify specific risk genes for schizophrenia and optimize treatment decisions for individual patients.
Dr. Owen is Founder and Director of the MRC Centre for Neuropsychiatric Genetics and Genomics and Director of the Institute of Psychological Medicine and Clinical Neurosciences at the Cardiff University School of Medicine where he is also Professor of Psychological Medicine and Deputy Head and Dean of Research. Dr. Owen has made pioneering and sustained contributions to schizophrenia and genetic research. In collaboration with Michael O’Donovan, Dr. Owen applies a combination of molecular genetic approaches to identify the specific genetic variants that confer risk of mental illness and has identified a large number for schizophrenia, demonstrating that many overlap with bipolar disorder.
The Colvin Prize for Outstanding Achievement in Mood Disorders Research
Eduard Vieta, Ph.D., University of Barcelona
Dr. Vieta is Professor and Head of the Department of Psychiatry and Director of the Bipolar Disorders Program of the Hospital Clinic at the University of Barcelona. He is also the Director of the Bipolar Research Program of the Spanish Research Network on Mental Diseases. Dr. Vieta has made remarkable contributions to the understanding and treatment of bipolar disorder that have helped improve the lives of millions of individuals with bipolar disorder around the globe. His studies range from those that have demonstrated the efficacy of the most widely used atypical antipsychotic?quetiapine (Seroquel®)?in monotherapy and combination therapy in the long term prevention of both manic and depressive episodes to one that showed the effectiveness of gabapentin (Neurontin®) as augmentation therapy in long term prophylaxis. He and his group have also pioneered in demonstrating the acute and lasting effectiveness of psycho-education and related psychotherapeutic approaches in the treatment of bipolar disorder.
Karen Dineen Wagner, M.D., Ph.D., University of Texas Medical Branch at Galveston
Dr. Wagner is the Marie B. Gale Professor and Vice Chair of the Department of Psychiatry and Behavioral Sciences at the University of Texas Medical Branch in Galveston and Director of the Division of Child and Adolescent Psychiatry. An internationally recognized expert in the treatment of childhood mood disorders, she has pioneered studies of childhood bipolar and unipolar mood disorders. Her work has helped in the development and implementation of the most optimal approaches to childhood bipolar disorder, increasingly recognized as a common, difficult to treat and often highly disabling disorder.
The Ruane Prize for Outstanding Achievement in Child and Adolescent Research
Matthew State, M.D., Ph.D., Yale University
Dr. State is the Donald J. Cohen Professor of Child Psychiatry, Psychiatry and Genetics, and Deputy Chairman for Research in the Department of Psychiatry at the Yale University School of Medicine. Dr. State represents a rare combination of a clinically trained child psychiatrist who also has received a Ph.D. in genetics. His research centers on the search to discover genes related to neuropsychiatric and neurodevelopmental disorders of childhood and is recognized as one of the most outstanding scientists in the discovery of rare genetic variants as risk factors for autism. Applying rapidly evolving technologies of molecular genetics, his work is helping to illuminate the molecular and neurobiological underpinnings of these disorders toward the goal of translating research findings into new and more effective treatments.
Daniel Geschwind, M.D., Ph.D., University of California, Los Angeles (UCLA)
Dr. Geschwind is the Gordon and Virginia MacDonald Distinguished Chair in Human Genetics and is a professor of neurology and psychiatry at the UCLA School of Medicine. He is director of the Neurogenetics Program and the Center for Autism Research and Treatment (CART) and co-director of the Center for Neurobehavioral Genetics at UCLA. In addition to his fundamental quest to understand the genetic basis of human higher cognition, Dr. Geschwind is working to develop effective, targeted therapeutics for brain and behavior disorders such as autism. He and his team integrate basic neuroscience investigations with advanced technologies, such as computational and bioinformatics methods and systems biology to analyze gene expression data in the brain. Dr. Geschwind also provided the leadership that led to the Autism Genetic Resource Exchange, a national resource for the study of Autism Spectrum Disorders.
The Goldman-Rakic Prize for Outstanding Achievement in Cognitive Neuroscience
Larry R. Squire, Ph.D., University of California, San Diego (UCSD)
Dr. Squire is a Distinguished Professor of Psychiatry, Neurosciences and Psychology at the UCSD School of Medicine and Research Career Scientist at the Veterans Affairs Medical Center in San Diego. Dr. Squire is one of the great contributors to neuroscience with research that is critical to both basic understanding and its application to clinically relevant processes. His path-breaking work on memory mechanisms has been of enormous importance and has been performed with exquisite care. He is also appreciated at a profound level for his unusual excellence as a thoughtful and gifted mentor able to bring out the best in others and as an educator who is effective at every level. In addition to more than 450 research articles, Dr. Squire is the author of Memory and Brain (Oxford Press, 1987) and co-author, with Scientific Council Member and Nobel Laureate Eric Kandel, M.D., of Memory: From Mind to Molecule (W.H. Freeman, 1999).
The Sidney R. Baer, Jr. Prize for Innovative Schizophrenia Research
James T. R. Walters, M.D., Ph.D., Cardiff University
Dr. Walters, a 2009 NARSAD Young Investigator Grantee, is Clinical Senior Lecturer at the United Kingdom’s Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics at Cardiff University, Wales. He is a highly promising young M.D., PhD, who is researching the nature and genetic basis of cognitive deficits in schizophrenia and related psychotic disorders. Dr. Walters demonstrated that a schizophrenia genetic risk variant in the gene ZNF804A (discovered by 2012 Lieber Prizewinners O’Donovan and Owen) has a counterintuitive action on cognition: it is more strongly associated with a subtype of the disorder characterized by preserved cognition. In other work, he identified a schizophrenia risk gene as being associated with episodic memory and with smaller volume in the hippocampus, a brain area involved in episodic memory deficits.
PRODUCTIVE LIVES AWARDEES
This year two individuals have been selected to be honored with the fifth annual Productive Lives Awards for extraordinary contributions toward therapy and recovery from mental illness.
The Honorable Judge Steven Leifman
Miami-Dade County Court Criminal Division
Judge Leifman has served as Special Advisor on Criminal Justice and Mental Health for the Supreme Court of Florida since 2007. As chair of the Court’s Mental Health Subcommittee, he led the examination of Florida’s approach to criminal justice and mental health to transform Florida’s Mental Health System.
Alice Medalia, Ph.D.,
Columbia University Medical Center
Dr. Medalia is an international leader in the field of psychiatric rehabilitation. She developed the widely used NEAR (Neuropsychological & Educational Approach to Remediation) model to help people with mental illness improve their thinking skills in such areas as attention, memory, processing speed and problem solving.
About the Brain & Behavior Research Foundation
The Brain & Behavior Research Foundation is dedicated to identifying the causes, improving treatments and developing prevention strategies for mental illnesses that affect an overwhelming one-in-four people in the United States. One hundred percent of all donor contributions for research are invested in NARSAD Grants. The Foundation was formerly known as NARSAD (an acronym for National Alliance for Research on Schizophrenia and Depression). Since 1987, the Brain & Behavior Research Foundation has awarded nearly $300 million in over 4,000 NARSAD Grants to scientists worldwide.
TA的其他文章: